Actor Melissa Gilbert recoiled at the sounds of gum chewing, chip crunching, nail tapping, and other everyday sounds—but she was well into adulthood before she discovered she has misophonia.

Recognized for her groundbreaking contributions to tissue reconstruction and hand transplantation, Linda Cendales, MD, a leading figure in hand transplant and microsurgery, will be inducted into the National Academy of Medicine in her native Colombia on Oct. 3.    

Faculty, students, and staff from across Duke came together for conversations on the intersection of science and equity, diversity, and inclusion at Duke University School of Medicine’s second annual Equity Advancement Symposium

Senior Resident Kate E. Lee, MD, MS, uses her flute as a therapeutic tool to soothe critically-ill ICU patients waiting for heart transplants.

Congresswoman Valerie Foushee (NC-04), visited Duke University to meet with Mary Klotman, MD, as well as leadership of the Duke Center for Brain and Spine Metastasis (DCBSM) and presented a copy of the resolution she introduced to Congress to establish Brain and Spine Metastasis Awareness Month.

Medical resident Jeffrey Lee, MD, is on a mission to understand the human side of illness. He partnered with patients on the narrative medicine project “Untold Stories,” to share their personal stories about living with illness.

Duke Health researchers report that some tobacco companies have begun replacing nicotine in e-cigarettes with related chemicals that have similar properties but unknown health effects, in what appears to be an effort to bypass public health regulations covering vaping products.

Duke University School of Medicine welcomes more than 630 students from across the country and around the world as they start their health professions careers at the School of Medicine this month.

Fatty liver disease happens when a person’s body begins to store fat in the liver, which can damage the organ. Some forms of fatty liver disease are caused by excessive alcohol use.

The FDA has approved a new targeted drug specifically for brain tumors called low-grade gliomas. The drug, vorasidenib, was shown in clinical trials to delay progression of low-grade gliomas that had mutations in the IDH1 or IDH2 genes.